Bioject Medical Technologies, Inc. (BJCT) - 500 Beiträge pro Seite
eröffnet am 17.10.07 16:30:31 von
neuester Beitrag 29.04.10 18:28:02 von
neuester Beitrag 29.04.10 18:28:02 von
Beiträge: 14
ID: 1.134.065
ID: 1.134.065
Aufrufe heute: 0
Gesamt: 2.205
Gesamt: 2.205
Aktive User: 0
ISIN: US09059T2069 · WKN: 874950
0,0001
USD
0,00 %
0,0000 USD
Letzter Kurs 05.04.16 Nasdaq OTC
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 0,5250 | +19,08 | |
| 5,8900 | +17,80 | |
| 1,9700 | +15,20 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -13,71 | |
| 3,0400 | -19,95 | |
| 1,9500 | -25,14 | |
| 1,6052 | -30,21 | |
| 0,5121 | -30,80 |
Feedback
Profile:Bioject Medical Technologies, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of needle-free drug delivery systems to pharmaceutical and biotechnology industries primarily in the United States. Its products include Biojector 2000 that enables healthcare professionals to deliver measured variable doses of medication through the skin, either intramuscularly or subcutaneously, without a needle; drug reconstitution system, which allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle; and Vitajet, a home-use self-injection solution for insulin. In addition, the company is developing Iject, a single prefilled disposable injector for self injection and pre-filled Biojector syringes. It has licensing and/or development agreements with Serono Laboratories, Inc., Merial, and the Centers for Disease Control and Prevention. The company was founded in 1985 and is based in Tualatin, Oregon.
http://www.bioject.com/
http://www.bioject.com/
Bioject Announces New Supply Agreement with Merck Serono
Thursday October 11, 9:30 am ET
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT - News), a leading developer of needle-free drug delivery systems, today announced that it has entered into a three-year supply agreement with Merck Serono, a division of Merck KGaA of Darmstadt, Germany, for the delivery of the cool.click(TM) and Serojet(TM) spring-powered needle-free device for use with Merck Serono's recombinant human growth hormone drugs.
"We are pleased to enter into this new agreement with Merck Serono, which is the continuation of our successful relationship with them," said Ralph Makar, newly appointed President and CEO of Bioject. "Merck Serono has been an excellent partner and we appreciate the confidence Merck Serono has in our proprietary needle-free technology. We look forward to continuing to supply them with our value-added spring-powered device and disposables for their recombinant human growth hormone drugs." Makar further commented, "We understand the importance and advantages of providing our needle-free technology for the delivery of such compounds as growth hormones and we are looking forward to expanding our technology in other fields."
Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
For more information on Bioject, visit www.bioject.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Bioject's expectations with respect to expanding the use of its needle-free technology in other fields. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that the Company's products will not be accepted by the market, the risk that the Company will be unable to successfully develop and negotiate new strategic relationships or maintain existing relationships, uncertainties related to the time required for the Company to complete research and development, obtain necessary clinical data and government clearances, and the risk that the Company may be unable to comply with the extensive government regulations applicable to Bioject's business. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.
Contact:
Bioject Medical Technologies Inc.
President and CEO
Ralph Makar, 503-692-8001 ext. 4137
or
Vice President of Finance
Chris Farrell, 503-692-8001 ext. 4132
--------------------------------------------------------------------------------
Source: Bioject Medical Technologies Inc.
Thursday October 11, 9:30 am ET
PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (Nasdaq:BJCT - News), a leading developer of needle-free drug delivery systems, today announced that it has entered into a three-year supply agreement with Merck Serono, a division of Merck KGaA of Darmstadt, Germany, for the delivery of the cool.click(TM) and Serojet(TM) spring-powered needle-free device for use with Merck Serono's recombinant human growth hormone drugs.
"We are pleased to enter into this new agreement with Merck Serono, which is the continuation of our successful relationship with them," said Ralph Makar, newly appointed President and CEO of Bioject. "Merck Serono has been an excellent partner and we appreciate the confidence Merck Serono has in our proprietary needle-free technology. We look forward to continuing to supply them with our value-added spring-powered device and disposables for their recombinant human growth hormone drugs." Makar further commented, "We understand the importance and advantages of providing our needle-free technology for the delivery of such compounds as growth hormones and we are looking forward to expanding our technology in other fields."
Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.
For more information on Bioject, visit www.bioject.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Bioject's expectations with respect to expanding the use of its needle-free technology in other fields. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that the Company's products will not be accepted by the market, the risk that the Company will be unable to successfully develop and negotiate new strategic relationships or maintain existing relationships, uncertainties related to the time required for the Company to complete research and development, obtain necessary clinical data and government clearances, and the risk that the Company may be unable to comply with the extensive government regulations applicable to Bioject's business. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.
Contact:
Bioject Medical Technologies Inc.
President and CEO
Ralph Makar, 503-692-8001 ext. 4137
or
Vice President of Finance
Chris Farrell, 503-692-8001 ext. 4132
--------------------------------------------------------------------------------
Source: Bioject Medical Technologies Inc.
Hiermit ist der Thread wieder eröffnet.
Viele Grüße
Andrea Kummermehr
Viele Grüße
Andrea Kummermehr
Totgeglaubte leben länger.
Es kommt wieder Leben rein.
Wachgeküsst!
Es kommt wieder Leben rein.
Wachgeküsst!
Der frühe Vogel fängt den Wurm.
Trading Spotlight
Antwort auf Beitrag Nr.: 37.235.765 von Pipifax am 22.05.09 18:52:55Sorry falsche URL.
Hier die richtige Adresse:
http://www.bioject.com/index.html
Hier die richtige Adresse:
http://www.bioject.com/index.html
Ebenso die Partnerschaft mit Vical gefällt mir sehr gut.
http://www.vical.com/products/Partnership_Programs.htm
http://www.vical.com/products/Partnership_Programs.htm
Geschrieben am 08.05.2009 auf dem BJCT.OB-Yahoo-Board:
Vical in 2006 established an in-licensing agreement with Bioject for certain vaccines. Vical is a biotech vaccine platform "pure play". Bioject is a needle free vaccine injection pure play.
Both companies have contracts and licensing agreements for veterinary and human vaccines. Both have impressive IP portfolios with US and international protections.
IMHO these two companies....BJCT and VICL are a great combo: WHY??
A) rising interest globally in pandemic vaccines,
B) big pharma interest in market growth in vaccines for infectious diseases, melanoma, PAD, HIV, CMV, etc.
C) increasing pressure for lower health care costs at scale and speed (including patient dosing), AND
D) announcements this week of CRADA funding for Malaria (BJCT) and Swine Flu (Vical), suggesting that the government (NIH, NIAID, VRC, Navy MRC) sees these companies as viable innovators whose time has come.
Now it could get very interesting!!!
Good luck.
Vical in 2006 established an in-licensing agreement with Bioject for certain vaccines. Vical is a biotech vaccine platform "pure play". Bioject is a needle free vaccine injection pure play.
Both companies have contracts and licensing agreements for veterinary and human vaccines. Both have impressive IP portfolios with US and international protections.
IMHO these two companies....BJCT and VICL are a great combo: WHY??
A) rising interest globally in pandemic vaccines,
B) big pharma interest in market growth in vaccines for infectious diseases, melanoma, PAD, HIV, CMV, etc.
C) increasing pressure for lower health care costs at scale and speed (including patient dosing), AND
D) announcements this week of CRADA funding for Malaria (BJCT) and Swine Flu (Vical), suggesting that the government (NIH, NIAID, VRC, Navy MRC) sees these companies as viable innovators whose time has come.
Now it could get very interesting!!!
Good luck.
Antwort auf Beitrag Nr.: 37.869.321 von Pipifax am 28.08.09 06:17:37Weier im Auge behalten.
Antwort auf Beitrag Nr.: 39.421.374 von Pipifax am 28.04.10 21:35:02Schon wieder eine Meldung:
http://finance.yahoo.com/news/Bioject-Announces-Results-of-b…
http://finance.yahoo.com/news/Bioject-Announces-Results-of-b…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,36 | |
| +0,98 | |
| -0,17 | |
| -9,90 | |
| -2,98 | |
| -0,06 | |
| -1,01 | |
| -1,14 | |
| -0,19 | |
| -0,76 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 240 | ||
| 98 | ||
| 81 | ||
| 79 | ||
| 75 | ||
| 53 | ||
| 41 | ||
| 38 | ||
| 36 | ||
| 33 |
